Real World Evidence
Meet your clinical, economic, and regulatory needs throughout a product's lifecycle using U.S. real world solutions.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSInstitute Report
Impact of RWE on HTA Decision-making
Dec 06, 2022
Report Summary
With clinical innovation accelerating, more drugs are obtaining marketing authorization for narrowly defined patient populations and early-stage disease. This can pose challenges in clinical evidence development, as fewer patients may be available for recruitment and generating mature outcomes can be prohibitively long.
Real-world evidence (RWE) has the potential to fill this gap by complementing and supplementing clinical trial evidence, as well as reducing health technology assessment (HTA) body uncertainties that can delay reimbursement decisions. As the momentum around RWE use strengthens, examples emerge where it has contributed to positive reimbursement decisions and therefore patient access to innovative therapies. However, acceptance of RWE in HTA evaluations and its impact on HTA outcomes remains limited and highly variable among countries.
This report explores the use of RWE in HTA evaluations to inform factors that are critical to the final pricing and reimbursement decision. It presents an overview of the current role of RWE in oncology HTAs, where unmet need and obstacles to developing clinical evidence are particularly high. The report then explores key drivers and barriers of historic RWE acceptance, which builds upon work presented at ISPOR Europe 2022 of 20 examples in oncology where RWE contributed to a positive HTA outcome. Considering the value of RWE in overcoming payer uncertainties and allowing for faster patient access, the report concludes with a discussion of initiatives and strategies to standardize and optimize the way RWE is evaluated across Europe.
Key Findings
- The use of RWE as a component of submissions in HTAs has seen a marked increase in recent years.
- According to an IQVIA analysis of 16,515 HTA reports across 83 HTA bodies spanning 33 countries, the proportion of records incorporating RWE as part of the submission has risen from just 6% in 2011 to 39% in 2021.
- Increases in use have been accompanied by papers showing the use of RWE to emulate RCTs with comparable results, while statements and guidance made by organizations such as the U.S. FDA reflect increasing acceptance by HTA and regulatory bodies.
- In three quarters of the examples in which RWE was seen to have a positive impact on HTA, the RWE provided external comparator data for the standard of care (SoC), namely in terms of effectiveness or real-world use.
- One notable example is the review of cemiplimab by the TLV, where the pivotal trial lacked a comparator arm and RWE provided data on BSC and platinum-based chemotherapy enabling cemiplimab’s advantages to be demonstrated.
- In the remaining quarter, RWE was used to provide data on intervention effectiveness, the validation of surrogate endpoints, and patient characteristics.
- At the national level, momentum is gathering to formalize the role of RWE in HTA, with several initiatives already having produced tangible results.
- France’s HAS published guidelines on the use of real-world studies in the assessment of medicinal products and devices in June 2021; in 2020, Canada’s CanREValue initiative developed a framework for the generation and use of RWE for cancer drug funding decisions; in Germany, which has historically been cautious in RWE adoption, the 2019 GSAV bill has opened the door to greater patient data registry use by allowing for the GBA to request data collection for orphan drugs that lack comparative data.